An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2012
At a glance
- Drugs JVS 100 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 30 Jan 2012 12-month results were presented at the 7th International Conference on Cell Therapy for Cardiovascular Disease, according to a Juventas Therapeutics media release. The results were also presented in the media release.
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 24 May 2011 Results were presented at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.